CliffBio
small molecule

DANZITEN

NILOTINIB TARTRATE

Loss of exclusivityFebruary 2040latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameDANZITEN
Active ingredientNILOTINIB TARTRATE
StrengthEQ 95MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2024
Marketing statusRX

Listed patents

PatentExpiresType
12629369February 2040product
12403140February 2040product
11793809February 2040product
10874671February 2040product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DANZITEN patent cliff — loss of exclusivity February 2040 | CliffBio